Growth Metrics

Alnylam Pharmaceuticals (ALNY) Net Margin (2009 - 2026)

Alnylam Pharmaceuticals posted quarterly Net Margin of 17.65% for Q1 2026, up 7849.0% year-on-year from 0.22% in Q1 2025, and up 73.58% on a QoQ basis from 10.17% in Q4 2025.

Alnylam Pharmaceuticals (ALNY) has 18 years of Net Margin data on file, last reported at 17.65% in Q1 2026.

  • For the quarter ending Q1 2026, Net Margin rose 7849.0% year-over-year to 17.65%; the trailing twelve-month figure through Mar 2026 stood at 12.69% (up 2561.0% YoY), and the FY2025 full-year result was 8.45%, up 2082.0% from the prior year.
  • Net Margin for Q1 2026 stood at 17.65%, up from 10.17% in the prior quarter.
  • Across five years, Net Margin topped out at 23.43% in Q3 2025 and bottomed at 153.58% in Q3 2022.
  • The 5-year median for Net Margin is 22.27% (2024), against an average of 39.7%.
  • The widest annual swing landed in 2023, when Net Margin surged 17327 bps; it then tumbled 4750 bps in 2025.
  • A 5-year view of Net Margin shows it stood at 61.93% in 2022, then jumped by 49 bps to 31.35% in 2023, then jumped by 55 bps to 14.12% in 2024, then jumped by 172 bps to 10.17% in 2025, then soared by 74 bps to 17.65% in 2026.
  • The last three Net Margin figures came in at 17.65% (Q1 2026), 10.17% (Q4 2025), and 23.43% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.82%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 34.53%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 20.17%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 17.65%
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 17.65%
Dec 31, 2025 10.17%
Sep 30, 2025 23.43%
Jun 30, 2025 -8.57%
Mar 31, 2025 -60.84%
Dec 31, 2024 -14.12%
Sep 30, 2024 -22.27%
Jun 30, 2024 -2.56%
Mar 31, 2024 -13.34%
Dec 31, 2023 -31.35%
Sep 30, 2023 19.69%
Jun 30, 2023 -86.59%
Mar 31, 2023 -54.53%
Dec 31, 2022 -61.93%
Sep 30, 2022 -153.58%
Jun 30, 2022 -123.39%
Mar 31, 2022 -112.70%
Dec 31, 2021 -99.97%
Sep 30, 2021 -109.00%
Jun 30, 2021 -85.95%
Mar 31, 2021 -112.80%
Dec 31, 2020 -148.90%
Sep 30, 2020 -201.26%
Jun 30, 2020 -172.40%
Mar 31, 2020 -183.18%
Dec 31, 2019 -385.30%
Sep 30, 2019 -297.65%
Jun 30, 2019 -490.86%
Mar 31, 2019 -546.39%
Dec 31, 2018 -1,005.28%
Sep 30, 2018 -11,855.10%
Jun 30, 2018 -546.90%
Mar 31, 2018 -644.84%
Dec 31, 2017 -375.03%
Sep 30, 2017 -719.10%
Jun 30, 2017 -743.28%
Mar 31, 2017 -565.88%
Dec 31, 2016 -648.76%
Sep 30, 2016 -765.31%
Jun 30, 2016 -1,034.89%
Mar 31, 2016 -1,401.96%
Dec 31, 2015 -1,201.44%
Sep 30, 2015 -1,214.29%
Jun 30, 2015 -821.55%
Mar 31, 2015 -276.25%
Dec 31, 2014 -181.02%
Sep 30, 2014 -400.31%
Jun 30, 2014 -608.49%
Mar 31, 2014 -3,248.50%
Dec 31, 2013 -298.30%
Sep 30, 2013 -330.17%
Jun 30, 2013 -209.15%
Mar 31, 2013 -48.35%
Dec 31, 2012 513.71%
Sep 30, 2012 -116.37%
Jun 30, 2012 -62.04%
Mar 31, 2012 -55.22%
Dec 31, 2011 211.09%
Sep 30, 2011 -63.67%
Jun 30, 2011 -67.06%
Mar 31, 2011 -77.93%
Dec 31, 2010 -32.70%
Sep 30, 2010 -34.81%
Jun 30, 2010 -54.97%
Mar 31, 2010 -50.17%
Dec 31, 2009 -29.26%
Sep 30, 2009 -37.97%
Jun 30, 2009 -92.28%